Is cefixime effective against Escherichia coli that is susceptible to cephalexin?

Cephalexin Susceptibility Does NOT Reliably Predict Cefixime Effectiveness Against E. coli

You cannot assume cefixime will be effective against E. coli based solely on cephalexin susceptibility, and should obtain specific susceptibility testing for cefixime or use an alternative agent with confirmed activity.

Why Cross-Resistance Occurs

Cephalexin (a first-generation cephalosporin) and cefixime (a third-generation cephalosporin) have different R1 side chains and distinct resistance mechanisms that make cross-susceptibility predictions unreliable 1:

• Cephalexin susceptibility primarily reflects the absence of high-level AmpC or ESBL production, but does NOT guarantee cefixime activity
• Cefixime resistance in E. coli commonly occurs through:
  • OmpF porin downregulation (which affects cefixime more than cephalexin) 2
  • ESBL production (CTX-M, TEM, SHV variants) that specifically hydrolyze third-generation cephalosporins 3, 4
  • These mechanisms can exist even when cephalexin remains active

The Critical Structural Difference

The FDA label explicitly states that cefixime has been shown to be active against E. coli in clinical infections 5, but this activity is independent of first-generation cephalosporin susceptibility. Research demonstrates that:

• Cefixime MICs against E. coli are typically ≤0.12 mg/L for wild-type strains 3
• However, ESBL-producing E. coli show 1 to 135-fold increases in cefixime MIC while potentially remaining cephalexin-susceptible 3
• The prevalence of ESBL-producing E. coli is now 75-86% in many clinical settings 4, 6

Clinical Implications

For urinary tract infections (the most common indication):

• If treating empirically and cephalexin was previously effective, this does NOT validate cefixime use
• Guidelines recommend ceftriaxone (parenteral third-generation cephalosporin) for E. coli infections requiring third-generation coverage 7
• Oral cefixime is listed as an alternative for UTI in infants >28 days old at 8 mg/kg/day 7, but only after confirming susceptibility

For other E. coli infections:

• Guidelines consistently recommend third-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime) for serious E. coli infections 8, 9
• These recommendations assume susceptibility testing has been performed
• Cefixime is NOT mentioned in guidelines for complicated intra-abdominal infections or meningitis caused by E. coli 8, 10

What You Should Do Instead

1. Obtain culture and susceptibility testing that specifically includes cefixime if oral therapy is desired
2. Use ceftriaxone (50 mg/kg IV/IM daily) if parenteral third-generation cephalosporin coverage is needed 7
3. Consider cefixime-clavulanate combination (400/125 mg PO q12h) if ESBL-producing E. coli is suspected and oral therapy is required, as clavulanate restores cefixime activity in 85% of ESBL isolates 11, 6
4. Reserve carbapenems for confirmed ESBL infections when oral options are inadequate 12

Common Pitfall to Avoid

Do not extrapolate susceptibility across cephalosporin generations. The statement "sensitive to cephalexin therefore sensitive to cefixime" represents a fundamental misunderstanding of beta-lactam resistance mechanisms. Each cephalosporin generation has distinct side chains, stability to beta-lactamases, and porin penetration characteristics that must be individually assessed 1, 3.